## SENTARA HEALTH PLANS

### PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process can be delayed.

# **Group Specific Benefit**

#### Drug Requested: Weight Management Drugs (select one of the following)

benzphetamine 50 mg	□ <b>Qsymia</b> <sup>®</sup> (phentermine/topiramate ER)
□ <b>Contrave</b> <sup>®</sup> (naltrexone HCl/bupropion HCl)	□ Saxenda <sup>®</sup> (liraglutide)
diethylpropion IR/ER	□ Wegovy <sup>®</sup> (semaglutide)
□ Lomaira <sup>™</sup> (phentermine hydrochloride USP)	□ Xenical <sup>®</sup> (orlistat)
phendimetrazine IR	□ <b>Zepbound</b> <sup>™</sup> (tirzepatide)
<b>D</b> phentermine HCL	

#### MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:			
Member Sentara #:			
Prescriber Name:			
	Date:		
Office Contact Name:			
Phone Number:			
DEA OR NPI #:			
DRUG INFORMATION: Author	prization may be delayed if incomplete.		
Drug Form/Strength:			
Dosing Schedule:	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Waish4.	Date:		

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

#### **Initial Authorization: 6 months**

Provider please note: If member was previously approved for the requested medication under an alternate health plan, please complete the reauthorization section of the PA form.

- □ Member must meet <u>ONE</u> of the following age requirements:
  - □ 18 years of age or older
  - Qsymia<sup>®</sup> only: 12 years of age or older with an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex
  - □ Wegovy<sup>®</sup> only: 12 years of age or older with an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex
  - □ Saxenda<sup>®</sup> only: 12 years of age or older <u>AND</u> has a measured body weight of at least 60 kg (132 lbs)
- □ If requesting Saxenda<sup>®</sup>, Wegovy<sup>®</sup> or Zepbound<sup> $^{\text{M}}$ </sup>, member is <u>NOT</u> using concurrent therapy with another GLP-1 receptor agonist prescribed for another indication (e.g., Mounjaro<sup>®</sup>, Ozempic<sup>®</sup>, Trulicity<sup>®</sup>, Rybelsus<sup>®</sup>)
- □ Member must have participated in a weight loss treatment plan (i.e. nutritional counseling, an exercise regimen and/or a calorie/fat-restricted diet) in the past 6 months and will continue to follow this treatment plan while taking an anti-obesity medication
- □ Provider must submit current height and weight measurements (verified by chart notes)

Height:	<b>Current Weight:</b>	BMI:	Date:	

- □ Member must meet <u>ONE</u> of the following BMI requirements:
  - □ BMI of 30 or greater
  - □ BMI of 27 or greater with co-morbid conditions that may include coronary artery disease, hypertension, congestive heart failure, diabetes, dyslipidemia, or sleep apnea

Comorbid Condition(s): \_\_\_\_\_\_ (verified by chart notes)

#### **Reauthorization: up to 12 months**

(Contingent upon member continuing to lose weight up to desired BMI; PA requests for anti-obesity drugs will not be renewed if a member's BMI is below 18.5)

Baseline measurements: (Baseline is defined as body measurements obtained prior to the start of the requested medication)

Height: \_\_\_\_\_ Current Weight: \_\_\_\_\_ BMI: \_\_\_\_\_ Date: \_\_\_\_\_

**Current measurements: (verified by chart notes)** 

Height: Current Weight: BMI: Date:

#### All of the following reauthorization criteria must be met:

□ Member must continue with weight loss treatment plan (i.e., nutritional counseling, an exercise regimen and/or a calorie/fat-restricted diet) while on medication for weight reduction

- □ Member must meet <u>ONE</u> of the following:
  - □ Member has achieved at least a 5% decrease in their weight within the initial approval period of 6 months as documented by their physician (Initial renewal length = 6 months)
  - □ Member has maintained initial 5% weight loss (Subsequent renewal length = 12 months)
- □ Member is compliant with requested medication (verified by pharmacy claims)
- □ Provider attests that member has <u>NOT</u> developed any negative side effects from requested medication
- □ Provider attests that member does <u>NOT</u> have any medical or drug contraindications to therapy with requested medication

#### Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required. \*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\* \*<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>\*